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Abstract
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Glucose transport in humans is a vital process which is tightly regulated by the endocrine system.
Specifically, the insulin hormone triggers a cascade of intracellular signals in target cells
mediating the uptake of glucose. Insulin signaling triggers cellular relocalization of the glucose
transporter protein GLUT4 to the cell surface, which is primarily responsible for regulated glucose
import. Pathology associated with the disruption of this pathway can lead to metabolic disorders,
such as type II diabetes mellitus, characterized by the failure of cells to appropriately uptake
glucose from the blood. We describe a novel simulation tool of the insulin intracellular response,
incorporating the latest findings regarding As160 and GEF interactions. The simulation tool
differs from previous computational approaches which employ algebraic or differential equations;
instead, the tool incorporates statistical variations of kinetic constants and initial molecular
concentrations which more accurately mimic the intracellular environment. Using this approach,
we successfully recapitulate observed in vitro insulin responses, plus the effects of Wortmanninlike inhibition of the pathway. The developed tool provides insight into transient changes in
molecule concentrations throughout the insulin signaling pathway, and may be employed to
identify or evaluate potentially critical components of this pathway, including those associated
with insulin resistance. In the future, this highly tractable platform may be useful for simulating
other complex cell signaling pathways.
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Insulin is known to be essential for regulating glucose levels intracellularly and in the blood,
as well as contributing to other carbohydrate and lipid metabolism in mammals (Banting,
1937). The insulin molecule is a small peptide hormone manufactured in the beta cells of the
pancreas (Gallenberger et al., 2012). Interruption of insulin signaling can result in high
blood glucose (hyperglycemia), which is associated with both life-long health complications
and acute life-threatening disease. Among these are mild insulin resistance, diabetes
mellitus, and metabolic syndrome (Beale, 2012). Unfortunately, the underlying etiologies of
these diseases are poorly understood. Understanding and simulating the cellular response to
insulin could lead to the development of new treatments.
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Many early processes in the insulin signaling pathway are clearly understood, with
downstream processes being the focus of the most recent studies. The key feature of insulin
signaling is the process whereby the cell translocates glucose transporters (GLUT4) from
intracellular endosomes to the cell surface, where they function via facilitated diffusion to
import glucose from the extracellular fluid (James et al., 1988). For this to take place, insulin
signaling activates intracellular pathways which facilitate GLUT4 translocation, in addition
to ancillary cellular functions not directly related to glucose uptake (Leto & Saltiel, 2012).
Thus, previous computational models, as well as the proposed simulation approach
described herein, annotate only the molecular interactions shown or anticipated to relate to
glucose uptake. Moreover, eventual recycling of insulin receptors and GLUT4 is an added
dimension of downstream regulation that is not addressed in this current approach.
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Figure 1 provides a simplified overview of the insulin signaling pathway. In Figure 1A,
following insulin release into the bloodstream, insulin is detected by target cells via binding
to the insulin receptor. Once insulin and the receptor have engaged, the insulin receptor
undergoes autophosphorylation. The signal is propagated as activated insulin receptors
phosphorylate downstream substrates. Insulin receptor substrates then activate
phosphoinositide 3-kinase (PI3K) which converts membrane lipids to phosphatidylinositol
(3,4,5)-triphosphate. Accumulation of phosphatidylinositol (3,4,5)-triphosphates are
necessary to Akt and phosphoinositide-dependent kinase (PDK) interaction, which results in
the double phosphorylation of Akt. Figure 1B shows the effector functions of insulin
signaling following Akt activation. Double phosphorylated Akt is able to turn off GTPase
activating proteins (GAPs), one of which is the Akt substrate of a 160 kDa size (As160). An
unstimulated cell contains active GAPs that are able to prevent GLUT4 vesicle translocation
through the prevention of accumulating RabGTP in GLUT4 endosomes. The inactivation of
GAPs such as the As160 through the insulin stimulated PI3K/Akt cascade results in the
accumulation of RabGTP's and ultimately GLUT4 translocation.
Traditionally, signaling pathways have been modeled using sets of differential equations
describing changes in molecular concentrations at rest and in response to upstream signals
(Chou and Voit, 2009). This approach, albeit useful, fails to readily incorporate random
variations of the kinetic constants (e.g., due to local temperature variations) and local
molecule concentrations (e.g., due to Brownian motion). To incorporate such random
variation, which more accurately mimics the intracellular environment, the proposed
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simulation platform mimics transitions of molecules involved in insulin signaling pathway
independently inside each considered cell as shown in Figure 2. Distinct from the traditional
approach, this “queuing theory” approach has been successfully used to accurately and
rapidly model packet transfer in data-dense telecommunication networks (Giambene, 2005).
Such an approach was recently reported to accurately delineate non-viral gene delivery
intracellularly (Wysocki et al., 2012).
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To confirm that the simulation accurately models cellular responses, we compare our data to
published results largely derived from human adipocyte studies. The simulation yielded
time-dependent changes in GLUT4 present at the cell surface consistent with published
observations for various insulin concentrations (Martin et al., 2006). Moreover, the platform
accurately simulated abnormal cellular conditions, such as inhibition of phosphoinositide 3kinase (Clarke et al., 1994; Hara et al., 1994). Furthermore, the simulator was employed to
independently demonstrate the critical role of the PTEN protein in insulin response.
Whereas previous models often mimicked known insulin responses, the proposed simulation
offers additional advantages. First, individual component concentrations and kinetic
constants can be derived if unknown or not well established (see Fig. 2, shaded area).
Second, the model is able to mimic a configurable cell population number. Finally, the
developed platform is extremely rapid: simulating responses within 100 cells for 1 min
required less than 10 compute minutes. Such rapid calculation can therefore be used to
extensively explore variations of concentrations or kinetics resulting in promotion of or
interference with the insulin pathway. Such an approach may help identify additional key
steps in the insulin pathway. Ultimately, this “queuing theory” approach may be more
broadly employable to additional signaling pathways. As a first step, further validation of
the simulation could verify that cells other than adipocytes respond to insulin in a similar
fashion.

Materials and Methods
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Kinetic constants and molecular concentration values were obtained via a Pubmed search for
publications within the last 50 years. Particularly useful were previous reports which
included multiple compiled, derived, or observed values (Faratian et al., 2009; Hatakeyama
et al., 2003; Kozka et al., 1995; Sedaghat et al., 2002; Shin et al., 2005; Stephan et al.,
2009). Values that were not available in the literature were estimated (below). Error values
associated with constants were used in the stochastic model when provided by sources. To
simplify the branching effect of downstream components of Akt in the insulin mediated
signal cascade, we use As160 to refer to multiple family members of Rab GAPs involved in
GLUT4 translocation. Thus, the derived kinetics for GAP effector functions are associated
with the family of downstream Akt effectors as a whole rather than the primary target of
As160. This is due to previous studies that have shown that, while As160 may be the
primary target of Akt in the insulin mediated pathway, it is not the only one (Eguez et al.,
2005).
During simulations, each simulated cell was calculated independently; that is, concentrations
of each molecule in the signaling chain (Fig. 2) is stochastic, and bound by the provided
error values. Implementation of the queuing theory approach causes that the actual
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concentrations of given molecule types in the cell are simulated as separate storages
(queues) for each cell. The probability of a movement happening at any time instant from
one queue to the next is determined by the relevant reaction speed. Movements between
storages happen at a particular time instant if a number randomly drawn from the interval
[0,1] at that time instant is smaller than the reaction speed governing the movement. After
simulations have been performed for every considered cell, the results are averaged over the
cell population. This queuing approach is therefore distinct from molecular dynamic
simulations and stochastic chemical kinetics. The current approach is most similar to
modeling information packets trafficking through a computer network using queuing theory
which utilizes the given service rates of particular nodes rather than by solving Maxwell's
equations for the individual links. Although differential equations are excellent tool to model
continuous time analog processes, discrete processes are better modeled using difference
equations that for random scenarios are well represented by the queues, where the input to
the queue is described by one difference equation and the output by another difference
equation. Connecting those queues into a network thus models a set of difference equations,
where the lengths of the queues provide instantaneous solutions. Such a queuing network
can be easily used to model scenarios where the arrival/service rates change dynamically
depending on the lengths of some queues in the system or where changes happen randomly.
Most of the kinetic constants used for the simulation are given in the literature with quite
wide margins, up to ±80%. Therefore, in the developed platform, the randomization of their
values was adopted through the following formula:
(1)

where k(i) is the value of the constant at the ith time instant, k is the average value of the
constant, m is the margin for the constant, such that
(2)
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and x(i) are Gaussian distributed random variable with a zero mean and a variance equal to 1
drawn at every consecutive time instant. A similar approach was taken in randomization of
initial concentrations; however, the concentrations were randomized only once per cell, at
the beginning of simulations, that is for i = 0. For constants/concentrations that have no
margins available in literature, a ±20% range was adopted, although the model is readily
adjustable to different ranges. Moreover, the simulation prohibits the very unlikely event of
kinetic constants being negative values, making it zero instead. Although Gaussian
distributions were assumed in the model, any other (e.g., uniform) distribution can be used if
desired.
In order to estimate values of kinetic constants V45, V46, (Fig. 2) and to approximate suitable
ranges for the kinetic constants needed to calculate V39 and the steady state number of free
RabGTP molecules in a cell, the final stages of the process have been computationally
imputed. A constant number of GLUT4 molecules localized at the cell surface in the
absence of insulin was assumed, as shown by Kozka et al. (1995) to be 18,000–20,000 per
Biotechnol Bioeng. Author manuscript; available in PMC 2014 December 01.
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cell. Published rates of GLUT4 vesicle translocation without insulin is 58,000 GLUT4
transferred to the plasma membrane per minute (Kozka et al., 1995), and 10 RabGTP
molecules are required to move one vesicle containing 20 GLUT4 molecules (Carvalho et
al., 2004; Kessler et al., 2000). Based on these values, and assuming that the formats of V45
and V46 are:
(3)

(4)

where RabGTP, Glut4Membrane, and As160 are the number of molecules of free RabGTP
molecules in the cell, the number of Glut4 molecules at the cell membrane, and the number
of As160 molecules in a cell, at a given time instant, respectively, one can calculate the
estimates for k45 and k46 (see Tables I and II). Because less is known about the interactions
between As160-RabGTPase and SNARE engagement of the GLUT4 vesicle, it is still
possible that a yet unobserved rate-limiting step may occur in this gap; however, this is
unlikely as our simulation accurately models multiple previous studies (Figs. 3 and 4).
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For the simulated pathway to stay stable in the absence of insulin, the number of RabGTP
molecules reacting with As160 (reaction speed V39) needs to be equal to the number of
RabGDP-GEF molecules being recycled back into RabGTP and GEF molecules,
respectively. Based on this assumption, the relationship
(5)

must hold without insulin applied. Solving these equations for the unknown kinetic
constants resulted in the about 18,200 GLUT4 at the cell surface in the absence of insulin
after 5 minutes (Fig. 3).
Except for Figure 5, all simulation-derived figures were averaged responses from 100 cells.
The simulation platform was implemented in MATLAB software and all the results were
obtained using 1 ms time increments, although the simulation allows the choice of any userselected time increment.

NIH-PA Author Manuscript

Results
Simulating Insulin-Dependent GLUT4 Translocation
It was first important to confirm that experimentally determined enzyme kinetics would be
mimicked by the simulation model. As increased GLUT4 concentrations on the plasma
membrane leads to productive influx of glucose, an effective measure of the outcome of
cellular activation by insulin signaling is the quantitation of GLUT4 vesicles activated for
translocation to the surface. As shown in Figure 3, the pathway achieves dynamic
equilibrium in pre-insulin (0 nM insulin) in vitro conditions by preventing increased GLUT4
transport to the cell surface. Due to the inherent stochastic nature of the approach used, a
non-trivial amount of cells were simulated for each plot (typically, 100 cells) and the
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average concentrations per cell were graphed. Adding validity, when extracellular insulin
concentrations are varied, the simulation mimics the response and timing of previously
studied in vitro conditions of glucose transport (Fig. 3). Differences between experimental
and simulated curves were analyzed by a series of Z-tests. For five of six data points where
mean and standard deviation of in vitro GLUT4 translocation has been reported as a
function of time and concentration of insulin, the in silico model was able to recapitulate the
results within one standard deviation (|Z| < 1.0). For all six data points, our in silico model
was able to recapitulate results within two standard deviations (|Z| < 2.0).
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Recent studies have shown that GLUT4 translocation is effected by Rab-GAP/GEF
interactions downstream of a PI3K/PDK/Akt signal cascade (Eguez et al., 2005; Larance et
al., 2005; Sano et al., 2003). As demonstrated in in vitro studies, As160, a GAP, plays a
pivotal role in regulating GLUT4 translocation (Sharma et al., 2010). During pre-insulin
conditions, As160 actively dephosphorylates Rab-GTP (present on the GLUT4 intracellular
vesicles) to Rab-GDP (Fig. 1). The resultant lack of Rab-GTP prevents Rab-GTP-dependent
GLUT4 vesicle translocation to the cell surface. Upon phosphorylation of As160 post
insulin binding at the insulin receptor, the phosphatase activity of As160 against Rab-GTP is
inhibited (Sano et al., 2003). The absence of As160 activity permits guanosine exchange
factor (GEF) activity to increase the amount of Rab-GTP present on the GLUT4 vesicle
(Eguez et al., 2005). Increased amounts of Rab-GTP on the surface of GLUT4 containing
vesicles catalyze intracellular vesicle translocation, membrane fusion, and incorporation of
the vesicle into the cell membrane, thereby depositing GLUT4. Upon deposition, the
GLUT4 molecules are active in importing glucose from the surrounding fluid.
Accurately Simulating Pathway Modulation on GLUT4 Translocation
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Beyond the ability to accurately simulate steady state or insulin activation, a third approach
to evaluate the simulation was a comparison of predicted and observed insulin mediated
GLUT4 translocation generated under disrupted conditions. Wortmannin, a fungal
metabolite, functions by inhibiting PI3K activity and is highly effective at interrupting
metabolic pathways that require PI3K dependent signal transduction (Okada et al., 1994). It
has been demonstrated in vitro that inhibition of PI3K activity results in complete cessation
of insulin stimulated GLUT4 translocation (Hara et al., 1994; James et al., 2004; Sharma et
al., 1998). To mimic the effects of wortmannin inhibition, the pathway was simulated by
substituting the steady state concentration of PI3K's substrate, PI, with multiple
concentrations below this steady state value. Simulating near complete inhibition of PI3K by
reducing PI levels yielded strong inhibition of insulin dependent GLUT4 translocation (Fig.
4A), in concordance with previous studies describing application of wortmannin (Clarke et
al., 1994; James et al., 2004).
As the role of As160 in GLUT4 translocation was only recently described, the effect of
varying concentrations of As160 which deviated from the standard-state values was
analyzed to investigate its role. GAP activity targeted at GLUT4 containing vesicles
prevents translocation of GLUT4 to the cell membrane, effectively inhibiting insulin
dependent glucose uptake (Sharma et al., 2010). As shown in Figure 4B, variation in the
effective concentration of As160 (which could be induced by an inhibitor or enhancer) has
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little effect on the cells ability to reach a maximal level of GLUT4 on the cell membrane in
response to insulin after 15 min. However, simulated changes in As160 effective
concentrations demonstrate a delay in GLUT4 translocation by a population of cells in
response to insulin. It is also possible that GEF activity is further stimulated beyond
increases caused by As160 inactivation; however, this is not established in vitro, but can be
effectively simulated.
Previously, phosphatase and tensin homolog (PTEN) has been shown to be a key target in
the control of diabetes (Butler et al., 2002). Experimentation with our simulation platform
highlighted this component as a key regulator in the insulin mediated GLUT4 translocation
pathway. Figure 4C demonstrates how small increases in PTEN cause major changes in the
cellular response to insulin stimulation.

NIH-PA Author Manuscript

One feature of signaling cascades, including the insulin signal cascade, is that on a per cell
basis, once an activation threshold for signaling has been reached, the signal cascade
proceeds in a robust and rapid form. To accurately mimic the effects of tissues, the presented
results are the averages as computed from 100 cells. Figure 5 demonstrates that there is no
significant difference among the curves obtained while averaging over 50, 100, or 500 cells
for the simulated scenarios.

Discussion
When studying disease it is important to understand the underlying processes involved. We
sought to simulate the insulin mediated GLUT4 translocation pathway with three novel
characteristics: (1) the pathway is the most complete representation of the required
components to date, especially those beyond As160; (2) the simulation platform
incorporates stochastic variations among individual cells and realistically mimics local
molecule availability in the signaling pathway, and (3) the response of hundreds of cells can
be simulated in near real-time. Previous models of insulin signaling have not included the
effector function of GLUT4 translocation, nor have they taken a simulation approach, but
rather a mathematical modeling approach.

NIH-PA Author Manuscript

Importantly, this novel simulation approach has recapitulated findings and observations of in
vitro studies. In the absence of insulin stimulation, results from simulation show essentially
no insulin mediated GLUT4 glucose influx, which is consistent with steady state values
determined in in vitro experiments (Fig. 3). For comparison to previously published in vitro
data which controlled the amount of insulin exposed to cells, we simulated the same
effective insulin concentration and observed the results (Martin et al., 2006). Again, the
simulation results accurately mimics results found in laboratory conditions, wherein very
low doses of insulin eventually lead to GLUT4 activation across exposed cells. The
simulation also predicts that increasing insulin dosage does not change the amount of
GLUT4 on each cell's surface in an arithmetic fashion; rather, the signal cascade occurs
when a given cell achieves an activation threshold. Consequently, low levels of insulin
dosage delays the average time it takes for an individual cell to receive and react to the
required signal. This concept is supported by previous findings that show insulin stimulates
GLUT4 activity in a quantal manner rather than a dose dependent increase in exocytosis
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and/or decrease in endocytosis rates (Coster et al., 2004; Stockli et al., 2011). Conversely,
delivering a dose 200-fold beyond physiologically normal activation levels does not
significantly increase the rate of GLUT4 translocation.
Following the validation of our simulation platform's ability to function in maintaining a
non-activated steady-state, and responding appropriately to insulin signals, we looked at its
ability to replicate in vitro experimental data resulting from disruption of the metabolic
pathway. First, we considered the inhibition of PI3K, known to be essential in transducing
the insulin signal. This was accomplished by adjusting the simulated level of PI, available to
PI3K (the target of the fungal metabolite wortmannin, which potently inhibits its function).
By lowering the effective concentration of PI3K substrate, we were able to generate results
that mimic wortmannin inhibition of PI3K: GLUT4 translocation being slowed or ultimately
limited. Studies of PI3K suggest that time course and signal amplitude contribute to the
specificity of the insulin signal (Tengholm and Meyer, 2002); once these pathways are
further deduced, the simulation can be readily modified to incorporate such understanding.
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Separately, GAP availability was simulated to more fully understand the effects of these
recently described processes. Uniquely, simulation results indicate that twofold overabundance of GAP activity delays maximum GLUT4 translocation to the cell surface by only 5
min, and the reverse is true for a twofold decrease in GAP activity. Lastly, we looked at the
effects of modulating PTEN. While several regulatory molecules elements are known to
have effects on the insulin pathway, only relatively small changes in PTEN activity have the
ability to completely shut down the insulin response. This correlates to recent studies which
implicate over-expression of PTEN as a strong negative regulator of the insulin signal
(Hiraku et al., 2001; Leslie and Downes, 2002). Additional studies have shown that PTEN
knockdown stimulates GLUT4 translocation to the cell membrane in an insulin dependent
manner (Liu et al., 2009). Interestingly, it has been reported that, although cellular amounts
of PTEN are independent of insulin resistance factors (i.e., obesity) in muscle cells, insulin
sensitization factors (i.e., regular exercise) can yield a decrease in the amount of PTEN
present in muscle cells in both obese and healthy organisms, pointing to a possible
mechanism by which regular exercise mitigates the effects of insulin resistance factors (Pons
et al., 2013). The simulation results indicate that relatively small increases (less than
twofold) are necessary to generate near zero response to insulin stimulation. The ability to
demonstrate the role of PTEN regulation on the insulin pathway suggests that the extensible
platform can accurately be used to simulate additional regulatory proteins as they are
discovered or hypothesized.

Conclusions
We have developed a metabolic simulation platform of insulin signaling utilizing a novel
stochastic theory approach which recapitulates experimental data. Moreover, the developed
platform has allowed us to validate previously published concentration estimates, as well as
derive concentrations for understudied components of the pathway. This was accomplished
by producing simulation results that agree with the well-established time courses between
insulin binding to its receptor and GLUT4 translocation. One caveat to comparing our
simulation results to the studies described herein is that much of the in vitro data is from the
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study of 3T3-L1 adipocytes. It is possible that GLUT4 regulation varies in muscle or
adipose tissues. Despite this, the extensibility and the ease of incorporating additional data
into our platform allows for the study of these differences as they become known. This
report can serve as a roadmap for additional experimental evaluations of under-documented
kinetics and concentrations. Moreover, the simulation platform produced average functions
at near real-time rates: the time required to simulate one minute of a single cell response
varied between 4.19 and 4.37 s. This suggests that the approach described here can be
expanded without significant decrease in usable performance. Lastly, the simulation was
built in MATLAB, and is entirely extensible, capable of including additional components, or
simulating completely new cellular pathways. In the future, it is anticipated that additional
components will be identified for the pathway which, when varied, potently affect the
outcome of insulin signaling. This approach would be useful to identify proteins for which
molecular inhibitors or activators would be effective in reducing dysregulation of the
pathway.
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Figure 1.
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Cartoon representation of the insulin dependent GLUT4 translocation from insulin binding
to its receptor to GLUT4-containing vesicles translocating to the outer cell membrane. This
figure summarizes the signal amplification pathway from insulin receptor binding to the
ultimate product of GLUT4 vesicle translocation. Details such as subunit composition (e.g.,
the insulin receptor tetramer), phosphorylation sites or mechanism, and relative
concentrations are not shown to provide simplicity. A: Insulin binding triggers a series of
phosphorylation events which propagates the insulin signal. B: Downstream Akt activation
leads to GLUT4 translocation to the cell surface. The representation highlights the recently
described role of the GAP As160 in regulating Rab dependent vesicular translocation. A
complete description is available in the text, and abbreviations are found in the glossary.
Image designed by Avery Mazor, © 2014.
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Figure 2.

Block model of the insulin signal transduction pathway. Schematic of the computational
model of insulin mediated GLUT4 translocation. Each block represents one intermediate in
the signal transduction pathway from insulin recognition to GLUT4 vesicle translocation.
Arrows between blocks are representative of a metabolic reaction between those two
intermediates. The rate of most metabolic reactions have been determined experimentally by
others. Labels on arrows refer to the enzyme kinetics attributed to that reaction. The
equations that correspond to these enzyme kinetics can be found in Table II. Component
abbreviations can be found in the glossary. This figure additionally illustrates the relative
level of understanding for kinetic parameters involved in different parts of this pathway.
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Figure 3.
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Comparison of in silico and in vitro models of insulin dependent GLUT4 translocation.
Simulated GLUT4 concentrations were plotted as averaged over 100 cell following insulin
stimulation in vitro. Simulations of insulin dosed at 200 nM, 0.5 nM, and 0 nMare plotted in
full lines. The cell membrane is loaded with approximately 10 × more GLUT4 molecules as
compared to the unstimulated cell. Data points will error bars represent experimentally
determined GLUT4 levels following both 200 nM (represented by thin rectangles) and 0.5
nM (represented by squares) doses of insulin, previously collected by others and replotted
here for comparison (Martin et al., 2006). A series of Z-tests were performed to determine
the significance in the differences between the in vitro and in silico models. Five of six time
points from simulated and measured in vitro experiments are within one standard deviation
(|Z| < 1.0). For one time point, the difference between GLUT4 translocation the in silico
model and the in vitro experiment was greater than one standard deviation (|Z| = 1.41).
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Figure 4.
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Modeling Insulin pathway alterations. A: The effects of phosphoinositide 3-kinase inhibitor,
wortmannin, on GLUT4 translocation. This figure illustrates the effects of reducing the
PI3K substrate concentration, PI, from its steady state level (300 nM) to lower levels (3 and
1 nM), which is comparable to the GLUT4-translocation inhibition by the fungal metabolite,
wortmannin, as a PI3K inhibitor. B: The effect of GAP activity on GLUT4 translocation. By
varying effective concentrations of GAP available compared to the initial concentration
(100%), the model demonstrates acceleration or delay in the translocation of GLUT4 to the
cell surface. C: The effects of PTEN concentration on GLUT4 translocation. Previous
observations demonstrate that PTEN levels significantly effect GLUT4 translocation, even
by small changes in PTEN concentration. Modeled results confirm that PTEN effective
concentration changes (increasing from 30 nM, nominally the physiological level)
negatively impact GLUT4 translocation. 10 Biotechnology
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Figure 5.

Utilizing various cell numbers in the computational model. To evaluate the effects of
stochastic-based modeling on averages calculated per cell, 50, 100 (used in all other
figures), and 500 cells were plotted using standard physiological induction concentrations.
Virtually no differences were detected between the models utilizing different cell numbers
over time.
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Glossary of terms, including definitions for symbols and abbreviations.
I = insulin
IR = insulin receptor
IR-I = single bound insulin to insulin receptor
pIR-I = phosphorylated single bound insulin to insulin receptor
|pIR-I| = internalized phosphorylated single bound insulin to insulin receptor
pIR-II = double bound insulin to insulin receptor
|pIR-II| = internalized phosphorylated double bound insulin to insulin receptor
IRS1/3 = insulin receptor substrates 1 through 3
pIRS1/3 = phosphorylated insulin receptor substrates 1 through 3
PI3K = phosphatidylinositol 3-kinase
pIRS1/3-PI3K = phosphorylated insulin receptor substrates 1 through 3, phosphatidylinositol 3-kinase, complex
PI3K* = activated phosphatidylinositol 3-kinase
pIRS1/3-PI3K* = phosphorylated insulin receptor substrates 1 through 3, activated phosphatidylinositol 3-kinase, complex
PI = phosphatidylinositol
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PI3K*-PI = activated phosphatidylinositol 3-kinase, phosphatidylinositol, complex
PIP3 = phosphatidylinositol (3,4,5)-triphosphate
PI3K*-PIP3 = activated phosphatidylinositol 3-kinase, phosphatidylinositol (3,4,5)-triphosphate, complex
PTEN = phosphatase and tensin homolog
PTEN-PI = phosphatase and tensin homolog, phosphatidylinositol, complex
PTEN-PIP3 = phosphatase and tensin homolog, phosphatidylinositol (3,4,5)-triphosphate, complex
pPTEN = phosphorylated phosphatase and tensin homolog
PTEN-PTEN = phosphatase and tensin homolog, phosphatase and tensin homolog, complex
pPTEN-PTEN = phosphorylated phosphatase and tensin homolog, phosphatase and tensin homolog, complex
Akt = protein kinase B
Akt-PIP3 = protein kinase B, phosphatidylinositol (3,4,5)-triphosphate, complex
pAkt-PIP3 = phosphorylated protein kinase B, phosphatidylinositol (3,4,5)-triphosphate, complex
PDK = phosphoinositide dependent protein kinase
ppAkt-PIP3 = double phosphorylated protein kinase B, phosphatidylinositol (3,4,5)-triphosphate, complex
PP2A = protein phosphatase 2
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PP2A-Akt-PIP3 = protein phosphatase 2, protein kinase B, phosphatidylinositol (3,4,5)-triphosphate, complex
PP2A-pAkt-PIP3 = protein phosphatase 2, phosphorylated protein kinase B, phosphatidylinositol (3,4,5)-triphosphate, complex
PP2A-ppAkt-PIP3 = protein phosphatase 2, double phosphorylated protein kinase B, phosphatidylinositol (3,4,5)-triphosphate, complex
ppAkt = double phosphorylated protein kinase B
PP2A-Akt = protein phosphatase 2, protein kinase B, complex
PP2A-pAkt = protein phosphatase 2, phosphorylated protein kinase B, complex
PP2A-ppAkt protein phosphatase 2, double phosphorylated protein kinase B, complex
As160 = Akt substrate of 160 kDa
pAs160 = phosphorylated Akt substrate of 160 kDa
PP2A-pAs160 = protein phosphatase 2, phosphorylated Akt substrate of 160 kDa, complex
PP2A-As160 = protein phosphatase 2, Akt substrate of 160 kDa, complex
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RabGTP = Rab G-protein in active guanosine triphosphate bound form
RabGTP-As160 = Rab G-protein in active guanosine triphosphate bound form, Akt substrate of 160 kDa, complex
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RabGDP = Rab G-protein in inactive guanosine diphosphate bound form
GEF = guanine exchange factor
RabGDP-GEF = Rab G-protein in inactive guanosine diphosphate bound form, guanine exchange factor, complex
GLUT4 = glucose transporter type 4
GAP = GTPase activating protein
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Kinetic constants and reaction equations used within the simulation.
Reaction equation

Kinetic constants

V0 = k0*[I]*[IR] – k – 0*[IR-I]

k0

0.06

k–0

0.2

±

Source
a

V1 = k1*[IR-I]

k1

2,500

a

V2 = k2*[pIR-I]

k2

0.2

a

V3 = k3*[pIR-I] – k – 3*[|pIR-I|]

k3

0.0021

a

k–3

0.00021

V4 = k4*[I]*[pIR-I] – k – 4*[pIR-II]

k4
k–4

V5 = k5*[pIR-II] – k – 5*[|pIR-II|]

V6 = k6*{[IRS1/3]([pIR-I] + [pIR-II])}/[IR] – k – 7*[pIRS1/3]
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V7 = k7*([pIRS1/3]*[PI3K] - kd,7*[pIRS1/3 – PI3K])

V8 = k8*[pIRS1/3-PI3K] – k – 8*[pIRS1/3-PI3K*]

V9 = k9*[pIRS1/3-PI3K*] - k – 9*[pIRS1/3*PI3K*]

20

k5

0.0021

k–5

0.00021

k6

4.16

k–6

1.4

k7

3

k d,7

1

k8

300

k–8
k9

a

0.06

a

a

1

a,b

30

a,b

0
b,c

13,500
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k–9

0

V10 = k10*[PI3K*]

V 10

900

130

b,c

V11 = k11*([PI]*[PI3K*] – kd,11*[PI3K*-PI])

k 11

0.03

0.006

b,c

k d,11

140

V12 = k12*[PI3K*-PI]

k 12

30

b,c

V13 = k13*[PI3K*-PIP3]

k 13

30

c

V14 = k14*([PIP3]*[PTEN] – kd,14*[PTEN-PIP3])

k 14

8,000

b,c

k d,14

0.01

0.004

V15 = k15*[PTEN-PIP3]

k 15

15

5

c

V16 = k16*[PTEN-PI]

k 16

3.6

1

c

V17 = Vmax,17*[PTEN]/(km,17 + [PTEN])

V max,17

150

50

c

0.4

c

V18 = k18*([PTEN]*[pPTEN] – kd,18*[pPTEN-PTEN])

V19 = kcat,19*[pPTEN-PTEN]

k m,17

2

k 18

1

k d,18

2.2

k cat,19

150

c
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Reaction equation

Kinetic constants

V20 = k20*[PTEN-PTEN]

k 20

150

c

V21 = k21*([PIP3]*[Akt] – kd,21*[Akt-PIP3])

k 21

15,000

b,c

k d,21

20

6

15,000

5,000

0.1

0.035

15,000

5,000

0.1

0.035

V22 = Vmax,22*[Akt-PIP3]/(km,22 + [Akt-PIP3])

V max,22
k m,22

V23 = Vmax,23*[pAkt-PIP3]/(km,23 + [pAkt-PIP3])

V max,23
k m,23

V24 = k24*([ppAkt-PIP3]*[PP2A] – kd,24*[PP2A-ppAkt-PIP3])

±

Source

b,c

b,c
c
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k 24

3

k d,24

0.1

V25 = kcat,25*[PP2A-ppAkt-PIP3]

k 25

45

V26 = k26*[pAkt-PIP3 ]*[PP2A]

k 26

3

c

V27 = k27*[PP2A-pAkt-PIP3]

k 27

0.3

c

V28 = kcat,28*[PP2A-pAkt-PIP3]

k 28

45

V29 = k29*[PP2A-Akt-PIP3]

k 29

30

c

V30 = k30*[ppAkt-PIP3]

k 30

30

d

V31 = k31*([ppAkt]*[PP2A] – kd,31*[PP2A-ppAkt])

k 31

3

d

k d,31

0.1

V32 = kcat,32*[PP2A-ppAkt]

k 32

45

20

d

V33 = kcat,33*[PP2A-pAkt]

k 33

45

20

d

V34 = k34*[PP2A-Akt]

k 34

30

d

V35 = Vmax,35*[As160]/(km,35 + [As160])

V max,35

0.00003288

e

k m,35
V36 = k36*([pAs160]*[PP2A] – kd,36*[PP2A-pAs160])

20

20

c

c

24,810
d
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k 36

3

k d,36

0.1

V37 = kcat,25*[PP2A-pAs160]

k 37

45

V38 = k29*[PP2A-As160]

k 38

30

d

V39 = (koff,As160 + kcat,As160)/(kM,As160/D)*[RabGTP]*[As160]

k off,As160

600

f

k cat,As160

324

k M,As160

230

D

250

V40 = koff,GEF*[RabGTP-As160]

k off,GEF

600

f

V41 = kcat,GEF*[RabGTP-As160]

k cat,GEF

234

f

V42 = (koff,GEF + kcat,GEF)/(kM,GEF/D)*[RabGDP]*[GEF]

k off,GEF

600

f

k cat,GEF

234

20

d

3
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Reaction equation

Kinetic constants

±

k M,GEF

3

3,860

Source
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D

250

V43 = koff,GEF*[RabGDP-GEF]

k off,GEF

600

f

V44 = kcat,GEF*[RabGDP-GEF]

k cat,GEF

234

f

V45 = k45*RabGTP

k 45

0.0059

d,g

V46 = k46*Glut4_Membrane*As160

k 46

1.30E–07

d,g

ki = nM–1 min–1; kd,i, km,I, kM,As160, and kM,GEF = nM; V = nM/min; koff,As160, kcat,As160, koff,GEF, and kcat,GEF = min–1; D = no
units.
a

Sedaghat et al. (2002).

b

Hatakeyama et al. (2003).

c

Faratian et al. (2009).

d

Estimated from data in footnote c.

e
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Shin et al. (2005).

f

Stephan et al. (2009).

g

Kozka et al. (1995).

NIH-PA Author Manuscript
Biotechnol Bioeng. Author manuscript; available in PMC 2014 December 01.

Jezewski et al.

Page 22

Table III

NIH-PA Author Manuscript

A description of the initial concentration, units, and the equations forming the basis of the modeling.
Label

Initial conc.

“±”

Units

Differential equations d[pathway component]/dt

I

1,200

—

nM

–V0 – V4

IR
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0.0009

—

nM

V2 – V0

IR-I

—

—

—

V0 – V1

pIR-I

—

—

—

V1 – V2 – V3 – V4

|pIR-I|

—

—

—

V3

pIR-II

—

—

—

V4 – V5 – V6

|pIR-II|

—

—

—

V5

IRS1/3

60

40

nM

V9 – V6

pIRS1/3

—

—

—

V6 – V7

PI3K

200

70

nM

V10 – V7

pIRS1/3-PI3K

—

—

—

V7 – V8

pIRS1/3-PI3K*

—

—

—

V8 – V9

PI3K*

—

—

—

V9 + V13 – V10 – V11

PI3K*-PI

—

—

—

V11 – V12

PI3K*-PIP3

—

—

—

V12 – V13

PIP3

—

—

—

V13 + V30 – V14 – V21

PI

300

30

nM

V16 – V11

PTEN-PIP3

—

—

—

V14 – V15

PTEN-PI

—

—

—

V15 – V16

PTEN

50

5

nM

V16 + V20 + V20 – V14 – V17 – V18

pPTEN-PTEN

—

—

—

V18 – V19

PTEN-PTEN

—

—

—

V19 – V20

pPTEN

—

—

—

V17 – V18

Akt

100

3

nM

V34 – V21

Akt-PIP3

—

—

—

V21 + V29 – V22

pAkt-PIP3

—

—

—

V22 + V27 – V23 – V26

PP2A-Akt-PIP3

—

—

—

V28 – V29

PP2A-pAkt-PIP3

—

—

—

V26 – V27 – V28

PP2A-ppAkt-PIP3

—

—

—

V24 – V25

PP2A

10

2.5

nM

V27 + V29 + V34 + V38 – V24 – V26 – V31 – V36

PP2A-Akt

—

—

—

V33 – V34

PP2A-pAkt

—

—

—

V32 – V33

PP2A-ppAkt

—

—

—

V31 – V32

ppAkt

—

—

—

V30 + V35 – V31 – V35

ppAkt-PIP3

—

—

—

V23 – V24 – V30

PDK

—

—

—

—

a
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Label

Initial conc.

“±”

Units

As160

108

—

nM

V38 + V40 + V41 – V35 – V39

pAs160

12

—

nM

V35 – V36

PP2A-pAs160

—

—

—

V36 – V37

PP2A-As160

—

—

—

V37 – V38

RabGTP

0.0965

—

nM

V40 + V44 – V39

RabGDP

0.8685

—

nM

V41 + V43 – V42

RabGTP-As160
GEF
RabGDP-GEF

Differential equations d[pathway component]/dt

—

—

—

V39 – V40 – V41

0.51

—

nM

V43 + V44 – V42

—

—

—

V42 – V43 – V44

a

The molecular interactions required for GLUT4 translocation are independent of PDK concentrations.
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